194206-03-6

Basic information

• Product Name: methyl N²-(tert-butoxycarbonyl)-N⁵-phenyl-L-glutaminate
• Synonyms: methyl N²-(tert-butoxycarbonyl)-N⁵-phenyl-L-glutaminate
• CAS NO: 194206-03-6
• Molecular Weight: 336.388
• Mol File: 194206-03-6.mol

Chemical Properties

• CAS DataBase Reference: methyl N²-(tert-butoxycarbonyl)-N⁵-phenyl-L-glutaminate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N²-(tert-butoxycarbonyl)-N⁵-phenyl-L-glutaminate(194206-03-6)
• EPA Substance Registry System: methyl N²-(tert-butoxycarbonyl)-N⁵-phenyl-L-glutaminate(194206-03-6)

Safety Data

• Hazardous Substances Data: 194206-03-6(Hazardous Substances Data)

Upstream product

• 72086-72-7 N-tert-butoxycarbonylglutamic acid methyl ester 
• 62-53-3 aniline 
• 13574-13-5 Boc-Glu(OBzl)-OH 

Downstream Products

• 142166-24-3 methyl N^α-{1-[(2,4-diaminopteridin-6-yl)methyl]indolin-5-ylcarbonyl}-N^δ-phenyl-L-glutaminate 
• 142165-83-1 methyl N^α-[(1-benzyloxycarbonylindolin-5-yl)carbonyl]-N^δ-phenyl-L-glutaminate 
• 142165-84-2 (S)-2-[(2,3-Dihydro-1H-indole-5-carbonyl)-amino]-4-phenylcarbamoyl-butyric acid methyl ester 
• 194206-07-0 methyl N^δ-phenyl-L-glutaminate 

Relevant articles and documents

Synthesis of l -Kynurenine and Homo- l -Kynurenine via an Aza-Fries Rearrangement

l -Kynurenine, a non-proteinogenic amino acid, is the primary metabolite of tryptophan via the kynurenine pathway. Kynurenine is involved in a variety of biological processes occurring in the human body, notably in the central nervous system. Thus, the st

PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).

Antirheumatic agents. III. Novel methotrexate derivatives bearing an indoline ring and a modified ornithine or glutamie acid

The synthesis, biological profile and structure-activity relationship of various methotrexate (MTX) derivatives bearing an indoline ring are described. In particular, Nδ-(3-carboxyphenyl)-Nα-[1-[(2,4-diaminopteridin- 6-yl)methyl]indoline-5-ylcarbonyl]-L-glutamine (3d), compared to MTX; exhibited an enhanced anti-proliferative effect on human peripheral blood mononuclear cells obtained from healthy volunteers.